Locust Walk Acquisition Corp. (LWACU)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Stephen T. Worland
Employees:
10
142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH, CA, 92075
(858) 925-8215
• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
eFFECTOR Therapeutics, Inc. engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E)
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|